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Abstract
Alzheimer’s disease (AD) and Creutzfeldt-Jakob disease (CJD) represent two distinct clinical entities belonging to a wider
group, generically named as conformational disorders that share common pathophysiologic mechanisms. It is well-
established that the APOE e4 allele and homozygosity at polymorphic codon 129 in the PRNP gene are the major genetic risk
factors for AD and human prion diseases, respectively. However, the roles of PRNP in AD, and APOE in CJD are controversial.
In this work, we investigated for the first time, APOE and PRNP genotypes simultaneously in 474 AD and 175 sporadic CJD
(sCJD) patients compared to a common control population of 335 subjects. Differences in genotype distribution between
patients and control subjects were studied by logistic regression analysis using age and gender as covariates. The effect size
of risk association and synergy factors were calculated using the logistic odds ratio estimates. Our data confirmed that the
presence of APOE e4 allele is associated with a higher risk of developing AD, while homozygosity at PRNP gene constitutes a
risk for sCJD. Opposite, we found no association for PRNP with AD, nor for APOE with sCJD. Interestingly, when AD and sCJD
patients were stratified according to their respective main risk genes (APOE for AD, and PRNP for sCJD), we found statistically
significant associations for the other gene in those strata at higher previous risk. Synergy factor analysis showed a
synergistic age-dependent interaction between APOE and PRNP in both AD (SF=3.59, p=0.027), and sCJD (SF=7.26,
p=0.005). We propose that this statistical epistasis can partially explain divergent data from different association studies.
Moreover, these results suggest that the genetic interaction between APOE and PRNP may have a biological correlate that is
indicative of shared neurodegenerative pathways involved in AD and sCJD.
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Introduction
Both Alzheimer’s disease (AD) and Creutzfeldt-Jakob disease
(CJD) are brain amyloidoses associated with old age. Although,
they represent two distinct clinical entities, AD and CJD are now
considered as part of a wider group generically named as
conformational disorders, and more specifically brain amyloidosis.
These two disorders share common pathophysiologic mechanisms
involving protein deposits in the brain due to the conversion of a
soluble, normal protein into an insoluble, aggregated form leading
to fatal degeneration [1–5]. From an etiological standpoint, both
AD and CJD can be classified as sporadic and familial forms (and
also as acquired in CJD). The sporadic cases (sporadic CJD –
sCJD- and late onset AD) represent the most frequent forms; and
although of unknown aetiology, several genetic risk factors have
been described. The APOE e4 allele is a major risk factor for AD
[6,7]; whereas homozygosity at polymorphic codon 129 (Met to
Val) in the PRNP gene is a well-established susceptibility marker
for human prion diseases [8]. However, the role of APOE in CJD
and PRNP in AD is matter of discussion.
Previous studies on the distribution of PRNP codon 129 in AD,
or the APOE e4 allele in CJD yielded conflicting results. Some
studies found an association between the PRNP codon 129 and AD
[9–11], while others did not [12–19]. Likewise, some studies found
an association between the presence of the APOE e4 allele and
CJD [20,21], while others reports were negative [22–27].
Since these disorders share several features, a genetic interaction
between these genes might determine susceptibility to both
diseases or modulate the clinical phenotypes. A potential genetic
interaction between APOE and PRNP genes has been rarely
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22090studied for CJD or AD. Furthermore, to our knowledge, an
analysis of the potential epistasis of these genes in both disorders by
using the same control population and statistical approach has
never been materialized. In this study, we investigated a possible
genetic interaction between APOE e4 allele and the polymorphic
codon 129 of the PRNP gene in both AD and sCJD populations.
Results
In this study, two different patient (AD and sCJD) and one
control populations were analyzed. The control group consisted of
335 subjects; 198 (59.1%) women and 137 (40.9%) men. Age at
study inclusion for control individual followed a non-normal
distribution with a mean of 73.2 years and standard deviation of
11.0 years. The AD group consisted of 474 patients diagnosed
with probable AD according to the NINCDS-ADRDA criteria;
323 were women (68.1%) and 151 were men (31.9%). Age at onset
for control individuals followed a non-normal distribution with a
mean of 74.568.2 years. The sCJD group (n=175) included 140
(80.0%) definite, neuropathologically verified patients, and 35
(20.0%) probable cases that were diagnosed with sCJD. The
gender distribution was 87 (49.7%) women and 88 (50.3%) men.
Age at onset for this group followed a non-normal distribution
with a mean of 67.3611 years. No statistically significant
differences in gender distribution or age at onset were found
between definite and probable sCJD cases.
Analysis of gender distribution showed statistically significant
differences between AD (p=0.010) or sCJD (p=0.049) patients
and the control group. Analysis of age distribution yielded
statistically significant differences for sCJD patients (p,0.001),
and for AD patients (p=0.006) compared to the control group.
Mean age and gender distribution of the control population were
intermediate between those of AD and sCJD cases, supporting its
validity as a common control group. In order to correct for
potential effects of the differential gender and age distributions,
odds ratios and synergy factors were obtained from logistic
regression algorithms controlling by age and gender.
The distribution of the polymorphic codon 129 of PRNP and
APOE genotypes in control subjects, AD and sCJD patients are
shown in Table 1. APOE polymorphic variants at codon 112 and
codon 158, as well as the allelic haplotypes e2/e3/e4, were in
Hardy-Weinberg equilibrium in the three populations studied. As
expected, the polymorphic codon 129 of the PRNP gene was in
Hardy-Weinberg equilibrium in the healthy control and AD
populations, but in clear disequilibrium (p,0.0001) in the sCJD
population.
APOE and PRNP in AD
As shown in Table 2, and previously repeatedly described in the
literature, we found an increased risk of AD in APOE e4 allele
carriers (OR=4.51). Interestingly, when this association was
studied in different strata according to PRNP codon 129 genotypes,
we observed an increase in the OR associated with the presence of
M129 alleles. Thus, the highest OR (7.28) was observed in
M129M homozygous, while the lowest OR in V129V homozy-
gous (2.06). The Mantel-Haenszel test for homogeneity indicated
that these two homozygous strata were statistically significant
different (p=0.026). The fact that the OR for each stratum is
different and the global OR appears to be an average OR
suggested an interaction between APOE and PRNP, rather than
PRNP acting as a confounding factor.
Additionally, we also observed a decreased risk of AD in APOE
e2 allele carriers (OR=0.50, 95% CI: 0.30–0.82, p=0.006).
Similar to the results with the APOE e4 allele carriers, when this
analysis was performed in the 3 different strata defined by PRNP
codon 129, we found a tendency to higher protection associated
with the presence of PRNP V129 alleles (M129M: OR=0.61, 95%
CI: 0.28–1.31, p=0.20; and M129V: OR=0.55, 95% CI: 0.25–
1.21, p=0.14; and V129V: OR=0.25, 95% CI: 0.07–0.91,
p=0.036).
The analysis of AD risk related to the status of PRNP codon 129
(Table 3) indicated a non-significant association trend for the
M129 allele (OR=1.23, p=0.057), as well as for the M129M
(OR=1.47) and M129V (OR=1.16) genotypes compared to
homozygous V129V for the whole AD population. However, after
stratification of AD subjects according to their APOE e4 status, we
found a clear association (OR=3.94, p=0.007) for M129M
homozygous only in APOE e4 carriers. In this APOE e4+ stratum,
the analysis of dose effect indicated a two-fold increase in AD risk
(OR=2.02, p=0.004) for each PRNP M129 allele carried. A
similar analysis for APOE e2 carriers did not show any significant
association in any strata.
Altogether, these findings suggested that the M129 allele of the
PRNP gene is a susceptibility genetic risk factor of AD only in
APOE e4 carriers and prompted us to further explore the potential
genetic interaction between APOE and PRNP in the AD
population. In order to study the combined gene effects, we
analyzed the risk of developing AD for subjects carrying both traits
(APOE e4 carriers and PRNP M129M homozygous) compared to
subjects without these traits (Table 4). M129M homozygous
subjects carrying at least one APOE e4 allele have a 7.68-fold
(p,0.0001) increased risk of developing AD compared to subjects
V129V with no APOE e4 alleles, which is higher than the expected
combined effect of the individual contributions of APOE e4 and
PRNP M129M, suggesting gene-gene interaction or epistasis
(Table 4, upper).
In order to measure the size and significance of the interaction,
we performed a synergy factor (SF) analysis following reported
methods. According to this analysis, we obtained a SF of 3.59,
which is statistically significant different (p=0.027) from 1;
indicating a synergistic interaction between two risk factors, APOE
e4 and M129M (Table 4, upper). A similar analysis by PRNP
alleles (M129 vs. V129) indicated a SF of 1.86 (p=0.018) for the
interaction APOE e4 and a M129 allele (Table 4, bottom).
PRNP and APOE in sCJD
As shown in Table 5, an increased risk for sCJD was associated
with M129M (OR=4.61) and V129V (OR=3.20) homozygous
compared to M129V heterozygous at codon 129 of the PRNP
gene. Interestingly, when these associations were studied in
different strata according to the APOE e4 status, we observed an
important increase in the OR for APOE e4 carriers compared to
non-e4 carriers (28.5 vs. 3.5 for M129M and 13.2 vs. 2.43 for
V129V). Mantel-Haenszel tests for homogeneity indicated that the
APOE e4 carriers were statistically significant different from APOE
e4 non-carriers for the M129M comparison (p=0.022). These
data, as in the case of the AD population, suggested an interaction
between APOE and PRNP in sCJD. The analysis of the APOE e4
allele dose effect (no, one or two copies of APOE e4 allele) showed
similar results, although of lower magnitude to the ones observed
for the e4+ and no-e4 allele comparison (M129M OR=2.26
p=0.023; M129V OR=0.68 p=0.48; V129V OR=1.26
p=0.68; Homozygosity OR=1.89 p=0.032), suggesting that
the effect of APOE e4 allele was dose dependent.
We found no association between APOE e4 allele status and
sCJD for the total population (OR=1.46, p=0.13) (Table 6).
However, when the different genotypes of PRNP codon 129 were
analyzed individually, a statistical significant risk associated with
APOE-PRNP Interaction in AD and CJD
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stratum (OR=2.47, p=0.017). We also found a similar trend,
although not statistically significant, in the V129V homozygous
stratum. Opposite, a non significant protector effect for the APOE
e4 allele was found in M129V heterozygous stratum. Mantel-
Haenszel test indicated significant differences between the M129M
homozygous and M129V heterozygous strata (p=0.022) or
homozygous (M129M and V129V) vs. M129V heterozygous
(p=0.027). We did not find association for the APOE e2, neither in
the unselected domain (all sCJD/control populations), nor in any
of the subpopulations defined by PRNP codon 129 genotypes.
In order to study the combined gene effects between APOE and
PRNP in sCJD, we analyzed the risk of developing sCJD for subjects
carrying both traits (APOE e4 carriers and PRNP homozygous)
compared to subjects without these traits (Table 7 top). PRNP
homozygous subjects carrying at least one APOE e4 allele have a
6.83-fold (p,0.0001) increased risk of developing sCJD than
subjects M129V heterozygous with no APOE e4 alleles. This
increased risk appears to be higher than a multiplicative effect of
each independent factor, suggesting gene-gene interaction or
epistasis. Synergy factor analysis yielded a SF of 7.26, which is
statistically significant different (p=0.005) from 1; indicating a
synergistic interaction between two risk factors, APOE e4a n dPRNP
homozygous. A similar analysis by PRNP genotypes (M129M vs.
M129V) indicated a SF of 8.48 (p=0.003) for the interaction APOE
e4 and PRNP M129M genotype (Table 7, bottom).
APOE and PRNP influence on disease onset and duration
We further explored the influence of these genetic factors on
disease onset for both AD and sCJD populations. In AD, we
Table 1. APOE and PRNP codon 129 genotypic and allelic frequencies in control subjects (Cont) and patients (AD, sCJD).
PRNP codon
129 APOE Genotypic frequency, n(%) APOE e4 status
a, n(%)
n e2/e2 e2/e3 e2/e4 e3/e3 e3/e4 e4/e4 e42 e4+
Cont Genotypes
M129M 129(100.0) 0(0.0) 14(10.9) 0(0.0) 101(78.3) 13(10.1) 1(0.8) 115(89.1) 14(10.9)
M129V 165(100.0) 1(0.6) 15(9.1) 0(0.0) 122(73.9) 27(16.4) 0(0.0) 138(83.6) 27(16.4)
V129V 41(100.0) 0(0.0) 10(24.4) 0(0.0) 22(53.7) 8(19.5) 1(2.4) 32(78.0) 9(22.0)
Total 335(100.0) 1(0.3) 39(11.6) 0(0.0) 245(73.1) 48(14.3) 2(0.6) 285(85.1) 50(14.9)
Alleles
M129 423(100.0) 1(0.2) 43(10.2) 0(0.0) 324(76.6) 53(12.5) 2(0.5) 368(87.0) 55(13.0)
V129 247(100.0) 1(0.4) 35(14.2) 0(0.0) 166(6.5) 43(17.4) 2(0.8) 202(81.8) 45(18.2)
Total 670(100.0) 2(0.3) 78(11.6) 0(0.0) 490(73.1) 96(14.3) 4(0.6) 570(85.1) 100(14.9)
AD Genotypes
M129M 215(100.0) 1(0.5) 8(3.7) 6(2.8) 106(49.3) 80(37.2) 14(6.5) 115(53.5) 100(46.5)
M129V 212(100.0) 0(0.0) 9(4.2) 3(1.4) 117(55.2) 71(33.5) 12(5.7) 126(59.4) 86(40.6)
V129V 47(100.0) 0(0.0) 4(8.5) 0(0.0) 26(55.3) 12(25.5) 5(10.6) 30(63.8) 17(36.2)
Total 474(100.0) 1(0.2) 21(4.4) 9(1.9) 249(52.5) 163(34.4) 31(6.5) 271(57.2) 203(42.8)
Alleles
M129 642(100.0) 2(0.3) 25(3.9) 15(2.3) 329(51.2) 231(36.0) 40(6.2) 356(55.5) 286(44.5)
V129 306(100.0) 0(0.0) 17(5.6) 3(1.0) 169(55.2) 95(31.0) 22(7.2) 186(60.8) 120(39.2)
Total 948(100.0) 2(0.2) 42(4.4) 18(1.9) 498(52.5) 326(34.4) 62(6.5) 542(57.2) 406(42.8)
sCJD Genotypes
M129M 112(100.0) 0(0.0) 12(10.7) 1(0.9) 75(67.0) 24(21.4) 0(0.0) 87(77.7) 25(22.3)
M129V 36(100.0) 0(0.0) 3(8.3) 0(0.0) 30(83.3) 1(2.8) 2(5.6) 33(91.7) 3(8.3)
V129V 27(100.0) 0(0.0) 5(18.5) 0(0.0) 13(48.1) 9(33.3) 0(0.0) 18(66.7) 9(33.3)
Total 175(100.0) 0(0.0) 20(11.4) 1(0.6) 118(67.4) 34(19.4) 2(1.1) 138(78.9) 37(21.1)
Alleles
M129 260(100.0) 0(0.0) 27(10.4) 2(0.8) 180(69.2) 49(18.8) 2(0.8) 207(79.6) 53(20.4)
V129 90(100.0) 0(0.0) 13(14.4) 0(0.0) 56(62.2) 19(21.1) 2(2.2) 69(76.7) 21(23.3)
Total 350(100.0) 0(0.0) 40(11.4) 2(0.6) 236(67.4) 68(19.4) 4(1.1) 276(78.9) 74(21.1)
aAPOE e4 status: e42=no copies of e4 allele, e4+=one or two copies of e4 allele.
doi:10.1371/journal.pone.0022090.t001
Table 2. Odds ratios for the association between Alzheimer’s
disease and APOE e4 carriers (vs. APOE e4 non-carriers) among
different strata defined by PRNP codon 129 genotypes.
Subjects OR (95% CI) p-value
All subjects 4.51 (3.16–6.45) ,0.0001
M129M 7.28 (3.92–13.50) ,0.0001
M129V 3.92 (2.36–6.50) ,0.0001
V129V 2.06 (0.77–5.48) 0.15
doi:10.1371/journal.pone.0022090.t002
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carriers (72.867.0 years vs. 75.768.8 years, p,0.001), in
agreement with previous reports [6,28]. We also observed a
non-significant trend for later onset of APOE e2 carriers compared
to non-e2 carriers (76.8610.8 years vs. 74.368.0 years, p,0.50),
as previously reported [29]. On the other hand, we did not find
any association with onset for the 3 different genotypes related to
the codon 129 of PRNP (M129M: 74.168.1 years, M129V:
74.768.0 years, V129V: 75.569.5 years, p=0.62).
For sCJD, we found a non-significant tendency for earlier onset
associated with the PRNP V129 allele (M129M: 68.4610.6 years,
M129V 66.6611.3 years, V129V: 63.0611.6 years, p=0.13).
Regarding APOE, we observed a later onset for APOE e2 carriers
compared to non-e2 carriers (72.267.8 years vs. 66.7611.2 years,
p=0.046) in agreement to previous reports [30]; while we failed to
detect any effect for the APOE e4 allele (67.8610.5 years vs.
67.2611.2 years, p=0.75), also in agreement with previous results
[27].
Additionally, we also explored the influence of these genetic
factors on disease duration in sCJD population. We observed a
significant longer disease duration in PRNP M129V heterozygous
compared to PRNP homozygous (p,0.001) (M129M: 5.364.5
months, M129V: 13.167.7 months, V129V: 4.961.4 months).
These results are in concordance with previous reports about the
classification sCJD in several subtypes characterized by a
combination of PRNP codon 129 status and the size of protease
resistant PrP
Sc fragments and disease phenotype [31,32]. On the
other hand, we did not find any association with disease duration
for either APOE e2 allele or APOE e4 allele carriers.
We also study whether the synergistic effects observed between
APOE e4 and PRNP M129 was age dependent. For this purpose,
we stratified cases and controls into two groups according to the
median age for patients and control population pooled together.
Analysis of AD risk related to the status of PRNP of the age
Table 3. Odds ratios for the association between Alzheimer’s
disease and PRNP codon 129 in different strata defined by
APOE e4 allele status (V129V genotype and V129 allele are
taken as reference or non-exposed).
Subjects OR (95% CI) p-value
All subjects
Genotypes
M129M 1.47 (0.91–2.36) 0.11
M129V 1.16 (0.72–1.85) 0.54
Alleles
M129 1.23 (0.99–1.52) 0.057
APOE e42 subjects
a
Genotypes
M129M 1.07 (0.61–1.90) 0.81
M129V 1.00 (0.57–1.74) 0.99
Alleles
M129 1.05 (0.81–1.36) 0.71
APOE e4+ subjects
b
Genotypes
M129M 3.94 (1.46–10.6) 0.007
M129V 1.83 (0.72–4.63) 0.21
Alleles
M129 2.02 (1.26–3.24) 0.004
aAPOE e42=no copies of e4 allele;
bAPOE e4+=one or two copies of e4 allele.
doi:10.1371/journal.pone.0022090.t003
Table 4. Synergy in AD population between APOE and PRNP genes.
PRNP codon 129 APOE e4 allele
a Controls AD OR (95% CI) SF (p-value)
M129M vs. V129V
b 22 32 30 Reference
+ 2 115 115 1.07 (0.61–1.87)
2 + 9 17 2.00 (0.77–5.21)
++ 14 100 7.68 (3.66–16.55) 3.59 (0.027)
M129 vs. V129
c 22 202 186 Reference
+ 2 368 356 1.05 (0.82–1.35)
2 + 45 120 2.90 (1.92–4.31)
++ 55 286 5.65 (3.98–8.02) 1.86 (0.018)
aAPOE e4 allele: 2=no copies of e4 allele, +=one or two copies of e4 allele;
bOR calculated by a logistic regression model controlling by age, linear values, and gender and using the PRNP6APOE interaction factor as third independent variable;
cOR calculated by chi-square.
doi:10.1371/journal.pone.0022090.t004
Table 5. Odds ratios for the association between CJD and
PRNP codon 129 in different strata defined by APOE e4 allele
status (M129V genotype is taken as reference or non-
exposed).
Subjects OR (95% CI) p-value
All subjects
M129M 4.61 (2.89–7.35) ,0.0001
V129V 3.20 (1.69–6.05) 0.0004
APOE e42 subjects
a
M129M 3.50 (2.13–5.74) ,0.0001
V129V 2.43 1.18–5.03 0.017
APOE e4+ subjects
b
M129M 28.5 (5.63–144.3) ,0.0001
V129V 13.2 (2.25–76.9) 0.004
aAPOE e42=no copies of e4 allele;
bAPOE e4+=one or two copies of e4 allele.
doi:10.1371/journal.pone.0022090.t005
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allele previously found in the APOE e4 carriers stratum (see
Table 3) was mainly determined by individuals with earlier onset
(onset before 74 years old: OR=2.33, 95% CI: 1.23–4.42,
p=0.009; onset at or after 74 years old: OR=1.47, 95% CI:
0.66–3.25, p=0.35) (see Figure 1, right).
Similarly, analysis of sCJD risk related to the APOE e4 status of the
age stratified data showed that the association for APOE e4p r e v i o u s l y
found in the PRNP homozygous strata (see Table 6) was mainly
driven by individuals with later onset (onset before 71 years old:
OR=1.64, 95% CI: 0.72–3.74, p=0.24; onset at or after 71 years
old: OR=3.27, 95% CI: 1.27–8.43, p=0.014) (see Figure 1, left).
Discussion
A considerable number of studies have addressed association
analysis of PRNP codon 129, a well-established genetic risk factor
for sCJD, with AD; as well as the association of APOE e4 allele, the
major genetic risk factor for late onset AD, with sCJD. While the
potential interaction between APOE and PRNP has been studied in
AD populations, yielding controversial results [9,11,14,16,33,34],
few reports on the potential interaction between APOE and PRNP
in sCJD have been published [24,27]. The idea of undertaking a
combined genetic analysis of sporadic AD and sCJD searching for
interactions was motivated by reports on: i) the potential role of
PrP in AD [35–41], and ii) because as brain amyloidoses, AD and
sCJD, share several epidemiologic features such as an age at onset
concordant with the clinical course duration, and vascular risk
factors well established for AD and recently suggested for sCJD
[3,42,43].
A part of our results mainly correspond to confirmatory data.
Subjects bearing at least one APOE e4 allele have 4.51-fold
increased risk of developing AD in comparison with those that do
not carry this allele (Table 2). Homozygosity at PRNP codon 129
increases risk of sCJD: 4.61-fold for M129M and 3.2-fold for
V129V compared to M129V heterozygous (Table 5). Analysis of
the risk attributable to PRNP in the overall AD population showed
a statistically non-significant association (Table 2), of similar size
and direction than the meta-analysis based on periodically
updated data published at http://www.alzgene.org/ [44]. A
similar analysis for the association of APOE in the overall sCJD
population showed no association for the APOE e4 allele (Table 5),
nor for the APOE e2 allele.
Hidden effects in overall analyses were unveiled by stratification
according to their respective main risk genes (APOE e4 allele status
for AD, and PRNP genotypes for sCJD). We found statistically
significant associations for the other gene in those strata at higher
previous risk (APOE e4 carriers for AD, and PRNP M129M
homozygous for sCJD), suggesting an underlying interaction
between APOE and PRNP as risk factors for both disorders (see
Tables 3 and 6). The synergy factor analysis in AD and sCJD
confirmed the interaction between these two genes as risk factors
in both AD (SF=3.59, p=0.027), and sCJD (SF=7.26, p=0.005)
(see Tables 4 and 7). Thus, subjects who carried a PRNP M129M
genotype and at least one APOE e4 allele for AD, or PRNP
homozygous subjects that carried at least one APOE e4 allele for
sCJD have an increased risk that represent a deviation from a
multiplicative model for the combined effects of these genetic
factors.
It is understandable that a genetic interaction or epistasis given
by statistical significant SF values does not necessarily correlate
with a biological epistasis [45]. Provided there is a biological
interaction, PRNP codon 129 appears to act a risk factor, at least in
part, by different molecular mechanisms in AD and sCJD. While
the risk of AD is associated with the PRNP M129 allele among
APOE e4 carriers, the increased risk of sCJD is associated with
PRNP codon 129 homozygous (both M129M and V129V).
Interestingly, we found that these interactions between PRNP
and APOE were also age-dependent for both disorders, but in
opposite directions (see Figure 1). While the increased risk of the
PRNP M129 allele on APOE e4 carriers was mainly associated with
individuals with earlier AD onset; the APOE e4 allele risk on PRNP
codon 129 homozygous was mainly patent in the population with
later sCJD onset. These results suggest that APOE and PRNP act as
risk factors with different age-related timings, perhaps in
Table 6. Odds ratios for the association between CJD and
APOE e4 carriers (vs. APOE e4 non-carriers) among different
strata defined by PRNP codon 129 genotypes.
Subjects OR (95% CI) p-value
All subjects 1.46 (0.89–2.38) 0.13
M129M 2.47 (1.18–5.16) 0.017
M129V 0.30 (0.067–1.34) 0.12
V129V 1.55 (0.46–5.25) 0.48
Homozygous (M129M+V129V) 2.14 (1.16–3.95) 0.015
doi:10.1371/journal.pone.0022090.t006
Table 7. Synergy in sCJD population between APOE and PRNP genes.
PRNP codon 129APOE e4 allele
a Controls sCJD OR (95% CI) SF (p-value)
Homozygous vs. Heterozygous
b 22 138 33 Reference
+ 2 147 105 3.25 (2.01–5.23)
2 + 27 3 0.29 (0.07–1.30)
++ 23 34 6.83 (3.45–13.51) 7.26 (0.005)
M129M vs. M129V
b 22 138 35 Reference
+ 2 115 90 3.45 (2.11–5.65)
2 + 27 4 0.29 (0.07–1.30)
++ 14 27 8.48 (3.87–18.61) 8.48 (0.003)
aAPOE e4 allele: 2=no copies of e4 allele, +=one or two copies of e4 allele;
bOR calculated by a logistic regression model controlling by age as a linear variable and gender, and introducing the PRNP6APOE interaction factor as third
independent variable.
doi:10.1371/journal.pone.0022090.t007
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sCJD. Thus, PRNP appears to be a genetic risk factor with an
influence early during aging both in AD and sCJD, while APOE e4
has a later expression. Several interrelated questions rise about the
roles of APOE and PRNP interaction. First, if they determine the
shape of the age-specific incidence curves shifting peaks in
different directions; second, if they are related to disease course
duration; third, if they are related to the vascular pathway and
determine susceptibility pointing to same or different gene-
environment interactions. Similarly, a recent report on rapidly
progressive Alzheimer’s disease has found that both APOE and
PRNP may modulate the phenotypic expression of the disease [46].
Central to both neurodegenerative pathologies is an analogous
proteolytic processing of a membrane protein (APP in AD, and
cellular PrP in prion disorders) that generates unstable, aggrega-
tion prone, neurotoxic fragments that are pathognomonic for each
disease (Ab peptides and PrP
Sc). The coexistence of AD and CJD
pathology in a subgroup of sCJD patients [47], the colocalization
of PrP
Sc and Ab peptides in amyloid lesions both in sCJD and AD
[48–52], and a synergist effect between AD and prion pathologies
[53] have suggested common pathways involved in the generation
or clearance of Ab peptides and PrP
Sc [47]. In this sense, some
appealing findings are starting to delineate shared regulatory
mechanism that involves the amyloid beta peptides and their
precursor protein (APP) and cellular PrP.
On one side, PrP regulates the levels of Ab peptides by
decreasing the cleavage of APP by BACE1 [35,36]. On the other
side, cellular PrP protein has been also identified as a high-affinity
receptor for Ab oligomers, the pathological species responsible for
Alzheimer’s disease, mediating their deleterious effects [37–41]. In
order to reconcile the diverse roles of cellular PrP in Ab
metabolism, it has been proposed a feedback loop where, in
Figure 1. Synergistic age-dependent interaction between APOE and PRNP in both AD and sCJD. Top: Synergy factor values for the
interaction PRNP codon 1296APOE e4 in sCJD (left) and AD (right). Middle: Age-dependent risk. Left: sCJD associated with APOE e4 allele in PRNP
homozygous with onset before or after 71 years old. Right: AD associated with the PRNP M129 allele in APOE e 4 carriers with onset before or after 74
years old. Bottom: Normalized age-specific frequency at clinical onset for sCJD (left) and AD (right) and at genetic testing in controls adjusted to a
normal distribution curve.
doi:10.1371/journal.pone.0022090.g001
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expression that in turn exerts an inhibitory effect on BACE1,
decreasing Ab levels. In AD, this feedback loop is disrupted by
ever-increasing levels of Ab oligomers that bind to cellular PrP
shifting its interaction with BACE1, and therefore, preventing its
regulation [35,54].
Cerf and collaborators [55] observed that apoE4 strongly
stabilizes Ab oligomers, besides its reduced ability to clear these
toxic forms of Ab [56–59]. At genetic level, Combarros and
collaborators [45] in a recent review about potential interactions
between genes pairs in AD, reported that so far the only
consistently replicated interaction was that between BACE1 exon5
GG and APOE4. In this paper, we are reporting the interaction
between PRNP M129M and APOE4 in AD. Having in mind these
facts, and based on the feed-back regulation discussed, we propose
a potential mechanism for biological epistasis between the APOE
e4 allele and the PRNP M129 allele in AD. According to this
model, we suggest that apoE4 preferential binding and stabiliza-
tion of Ab oligomers favour Ab delivery to cellular PrP, instead of
its targeting for cellular clearance; therefore disrupting the
regulatory feed-back. Moreover, apoE has been shown to promote
Dab1 phosphorylation that in turns regulates APP processing [60].
ApoE4 compared to apoE3 results in lower levels of phophory-
lated Dab1 and increased levels of Ab peptides [58,60]. In AD
pathogenesis, Ab oligomers may further sequester apoE, preclud-
ing regulation of APP processing mediated by Dab1, and
promoting processing by BACE1 as above discussed.
The question whether the PRNP polymorphism affect the
interaction of Ab oligomers with cellular PrP was already posed by
Kim and Tsai [61]. Interestingly, Parkin and collaborators [35]
found an increase in Ab40 peptide levels in brains of M129M mice
compared to V129V, suggesting that cellular PrP M129 is less
efficient inhibiting BACE1 activity. We propose that cellular PrP
V129 could have a protective role in AD through a stronger
inhibitory effect on BACE1 activity and weaker affinity for Ab
oligomers as a consequence of its particular structure.
As previously discussed, homozygosity at PRNP codon 129 is the
main genetic driving force in sCJD disease [62] that correlates
with a increased tendency to form toxic self-propagating PrP
Sc
oligomers [63,64]. A model where apoE4 stabilizes PrP oligomers,
and impairs their clearance may also explain the synergistic
association between PRNP and APOE in sCJD. Moreover, similar
to apoE, PrP
Sc has been shown to affect to Dab1 phosphorylation
and Ab production [65,66]. These data appear to explain the
inverse correlation between PrP
Sc deposits and Abeta plaques in
sCJD and animal models [35,66]; and suggest new routes of
convergence for AD and prion pathologies. Future studies are
needed to elucidate the role of apoE4 in relation with cellular PrP
and PrP
Sc oligomers for the development of the disease. However,
analogously to AD, other effects of apoE-independent from PrP
metabolism, such as cholesterol transport and synaptic plasticity
and repair, and vascular implications may prove to be relevant for
sCJD [67–70,43].
In our opinion, this study has several features of relevance. We
have investigated for the first time, APOE and PRNP genotypes
simultaneously in the sporadic forms of AD and CJD compared to
the same control population, with an age distribution intermediate
between sCJD and AD cases. Potential bias by population
stratification was minimized by selection of ethnically matched
cases and controls from limited sources. Finally, the analysis of
sCJD includes an important number of patients with definite
diagnosis by anatomopathological study.
Unfortunately, the study has also limitations. Most important,
the AD cases are selected solely on a clinical diagnosis basis; no
anatomopathologically confirmed AD cases were included.
Moreover, since our AD cases are not completely characterised
by genetic analysis, some cases may correspond to genetic cases.
However, given the low frequency of familial cases, and that all
our AD cases are over 55 years with no aggregation of early onset
cases in their family, it is unlikely that this fact may alter the results
here discussed. Also, although the study populations are relative
large, there are a small number of cases in some less frequent strata
that may pose an increased risk of false positive results. Finally,
only a limited sample of a Spanish population is included in the
analysis, and therefore, perhaps the results are not suitable for
other populations.
Discrepancies among results, including ours, can be related to
ethnic differences or to the presence of additional factors
influencing risk that are not included in the analyses [71–73].
Some authors have suggested that the lack of replication among
different studies could be also related to epistasis or gene-gene
interaction [45,74,75]. Of special relevance for this work, it is the
study by Combarros and collaborators [12]; where opposite to our
results, they did not find any association for the PRNP gene with
the risk of developing AD, even after stratifying by APOE e4 allele
status in a Spanish population. Taking into account that even in
our study the association effect is small; this discrepancy may be
explained by the different geographic distribution of the studied
populations that may play an important role in the interpretation
of the results [16,45,76]. Thus, although both populations are of
Spanish origin, Combarros’ population is restricted to North of
Spain, while ours have been recruited mainly from two different
Spanish geographical areas (Eastern and Central areas). Perhaps
most relevant, having in mind that we have found an age-
dependent epistasis, the discrepancy between the two studies can
be related to the different age distributions for the AD patients and
controls included in these studies.
In summary, our data confirmed APOE e4 and homozygosity at
PRNP as major genetic risks for developing AD and sCJD,
respectively. More interestingly, we found statistically significant
age-dependent epistasis between these genes for both AD and
sCJD, suggesting common pathways involved in the generation,
clearance and neurotoxic signal transduction of Ab peptides and
PrP in AD and sCJD. Additional studies exploring larger
populations are required to confirm our findings.
Materials and Methods
Patients and controls
Study population was composed of 474 AD patients diagnosed
as ‘‘probable AD’’ according to NINCDS-ADRDA criteria [77]
(patients with family history of dementia were not included), 175
sCJD patients and 335 control subjects with normal cognitive
status. All subjects were Caucasians of Spanish origin (Eastern and
Central areas). The study was approved by the Bioethics and
Animal Welfare Committee (Comite ´ de Bioe ´tica y Bienestar
Animal) from the Instituto de Salud Carlos III, Madrid, Spain;
and by the Ethical Research Committees (Comite ´s de E ´tica en la
Investigacio ´n) from the CIEN Foundation, and Universidad
Auto ´noma de Madrid, Madrid, Spain. All samples for sCJD cases
analyzed in this study were obtained from patients with suspected
prion diseases, submitted for diagnostic purposes under the
guidelines of the Spanish National Referral and Surveillance
system. AD and control samples were obtained with the adequate
understanding and written consent of subjects, family members or
legal guardians, as appropriate. For this study, all samples were
coded and personal information dissociated from the test results,
according to local legislation at the time of analysis. All the data
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been conducted according to the principles expressed in the
Declaration of Helsinki.
DNA analysis
Total DNA was isolated from peripheral blood or cerebral tissue
following standard procedures. Genotyping of APOE polymor-
phisms (rs429358 and rs7412) was determined by Real-Time PCR
[78] or with FRET probes [79] and the analysis of the
polymorphism at codon 129 of the PRNP gene (rs1799990) was
performed by DNA sequencing using specific primers [80].
Statistical methods
Statistical analyses of nominal or categorical variables were
performed by Fisher’s exact text or Pearson’s chi-square test.
Quantitative variables (age at onset, disease duration) were
analyzed by non-parametric statistical hypothesis contrast with
Mann-Whitney U test. Additionally, logistic regression models
controlled by age (as a linear variable) and gender were used to
compare genotypic and allelic frequencies and to calculate
association adjusted odds ratio (OR) and 95% confidence intervals
(CIs). The Hardy-Weinberg test for genotype frequency distribu-
tions was performed on the observed genotype frequencies for
population, with significance based on a standard observed-
expected 2 with 1 df. The Mantel-Haenszel test was used to
estimate the common odds ratio and to test whether the overall
degree of association across different genotype strata was
significant. Deviations from normality of quantitative variables
were checked by the Kolmogorov-Smirnov statistic with Lilliefors’
significance. The synergy factor (SF), confidence intervals and
significance were calculated as previously described [45,81]. All
statistical analyses were performed with the GraphPad 4 or
PASWStatistics 18 softwares.
Acknowledgments
We thank the CIEN Foundation and Drs. P. Gil and P. Coria for the
recruitment of the Alzheimer’s cases, and to I. Sastre for her excellent
technical work in the management of the DNA bank. We also thank the
epidemiological and clinical coordinators for assistance and notifying cases
to the CJD Spanish Registry, as well as to F. Avellanal, J. Almaza ´n, M.
Ruiz, and E. Alcalde for their collaboration with the Spanish CJD
surveillance system. We are grateful to the Asociacio ´n para las Familias con
Alzheimer (AFALcontigo) from Madrid for their help. This work was made
possible by the generous participation of patients, control subjects and their
families.
Author Contributions
Conceived and designed the experiments: OC MJB MC. Performed the
experiments: OC MJB. Analyzed the data: OC MC. Contributed
reagents/materials/analysis tools: MJB JC AF PMM AL MJR AR RB
TGI FV JdP-C IF MC. Wrote the paper: OC JdP-C MC. Critical revision
of the manuscript: MJB JC AL IF.
References
1. Gambetti P, Russo C (1998) Human brain amyloidoses. Nephrol Dial
Transplant 13 Suppl 7: 33–40.
2. Checler F, Vincent B (2002) Alzheimer’s and prion diseases: distinct pathologies,
common proteolytic denominators. Trends Neurosci 25(12): 616–620.
3. Aguzzi A, Haass C (2003) Games played by rogue proteins in prion disorders
and Alzheimer’s disease. Science 302(5646): 814–818.
4. Armstrong RA, Lantos PL, Cairns NJ (2005) Overlap between neurodegener-
ative disorders. Neuropathology 25(2): 111–124.
5. Barnham KJ, Cappai R, Beyreuther K, Masters CL, Hill AF (2006) Delineating
common molecular mechanisms in Alzheimer’s and prion diseases. Trends
Biochem Sci 31(8): 465–472.
6. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, et al.
(1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s
disease in late onset families. Science 261(5123): 921–923.
7. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-
Vance MA, et al. (1993) Association of apolipoprotein E allele epsilon 4 with
late-onset familial and sporadic Alzheimer’s disease. Neurology 43(8):
1467–1472.
8. Mead S (2006) Prion disease genetics. Eur J Hum Genet 14(3): 273–281.
9. Golanska E, Hulas-Bigoszewska K, Rutkiewicz E, Styczynska M, Peplonska B,
et al. (2004) Polymorphisms within the prion (PrP) and prion-like protein
(Doppel) genes in AD. Neurology 62(2): 313–315.
10. Riemenschneider M, Klopp N, Xiang W, Wagenpfeil S, Vollmert C, et al.
(2004) Prion protein codon 129 polymorphism and risk of Alzheimer disease.
Neurology 63(2): 364–366.
11. Gacia M, Safranow K, Styczyn ´ska M, Jakubowska K, Pepłon ´ska B, et al. (2006)
Prion protein gene M129 allele is a risk factor for Alzheimer’s disease. J Neural
Transm 113(11): 1747–1751.
12. Combarros O, Sa ´nchez-Guerra M, Llorca J, Alvarez-Arcaya A, Berciano J, et al.
(2000) Polymorphism at codon 129 of the prion protein gene is not associated
with sporadic AD. Neurology 55(4): 593–595.
13. Casadei VM, Ferri C, Calabrese E, Grimaldi LM, Franceschi M, et al. (2001)
Prion protein gene polymorphism and Alzheimer’s disease: one modulatory trait
of cognitive decline? J Neurol Neurosurg Psychiatry 71(2): 279–280.
14. Dermaut B, Croes EA, Rademakers R, Van den Broeck M, Cruts M, et al.
(2003) PRNP Val129 homozygosity increases risk for early-onset Alzheimer’s
disease. Ann Neurol 53(3): 409–412.
15. Li X, Rowland LP, Mitsumoto H, Przedborski S, Bird TD, et al. (2005) Prion
protein codon 129 genotype prevalence is altered in primary progressive
aphasia. Ann Neurol 58(6): 858–864.
16. Del Bo R, Scarlato M, Ghezzi S, Martinelli-Boneschi F, Fenoglio C, et al. (2006)
Is M129V of PRNP gene associated with Alzheimer’s disease? A case-control
study and a meta-analysis. Neurobiol Aging 27(5): 770.e1–770.e5.
17. Poleggi A, Bizzarro A, Acciarri A, Antuono P, Bagnoli S, et al. (2008) Codon
129 polymorphism of prion protein gene in sporadic Alzheimer’s disease.
Eur J Neurol 15(2): 173–178.
18. Cousin E, Mace ´ S, Rocher C, Dib C, Muzard G, et al. (2009) No replication of
genetic association between candidate polymorphisms and Alzheimer’s disease.
Neurobiol Aging, 2009 Nov 2. [Epub ahead of print].
19. Schjeide BM, McQueen MB, Mullin K, DiVito J, Hogan MF, et al. (2009)
Assessment of Alzheimer’s disease case-control associations using family-based
methods. Neurogenetics 10(1): 19–25.
20. Amouyel P, Vidal O, Launay JM, Laplanche JL (1994) The apolipoprotein E
alleles as major susceptibility factors for Creutzfeldt-Jakob disease. The French
Research Group on Epidemiology of Human Spongiform Encephalopathies.
Lancet 344(8933): 1315–1318.
21. Van Everbroeck B, Croes EA, Pals P, Dermaut B, Jansen G, et al. (2001)
Influence of the prion protein and the apolipoprotein E genotype on the
Creutzfeldt-Jakob Disease phenotype. Neurosci Lett 313(1–2): 69–72.
22. Saunders AM, Schmader K, Breitner JC, Benson MD, Brown WT, et al. (1993)
Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer’s disease
and in other amyloid-forming diseases. Lancet 342(8873): 710–711.
23. Zerr I, Helmhold M, Armstrong VW, Weber T (1995) Apolipoprotein E in
Creutzfeldt-Jakob disease. Lancet 345(8941): 68–69.
24. Salvatore M, Seeber AC, Nacmias B, Petraroli R, D’Alessandro M, et al. (1995)
Apolipoprotein E in sporadic and familial Creutzfeldt-Jakob disease. Neurosci
Lett 199(2): 95–98.
25. Friedman G, Gabizon R, Ben-Yehuda A (1997) Apolipoprotein Eepsilon4 allele,
a risk factor for late onset nonfamilial Alzheimer’s disease among Israeli Jews.
Arch Gerontol Geriatr 24(2): 175–181.
26. Zerr I, Helmhold M, Poser S, Armstrong VW, Weber T (1996) Apolipoprotein
E phenotype frequency and cerebrospinal fluid concentration are not associated
with Creutzfeldt-Jakob disease. Arch Neurol 53(12): 1233–1238.
27. Varges D, Jung K, Gawinecka J, Heinemann U, Schmitz M, et al. (2011)
Amyloid-b 1–42 levels are modified by apolipoprotein E e4 in Creutzfeldt-Jakob
disease in a similar manner as in Alzheimer’s disease. J Alzheimers Dis 23(4):
717–726.
28. Chapman J, Korczyn AD, Karussis DM, Michaelson DM (2001) The effects of
APOE genotype on age at onset and progression of neurodegenerative diseases.
Neurology 57(8): 1482–1485.
29. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, et al.
(1994) Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer
disease. Nat Genet 7(2): 180–184.
30. Pickering-Brown SM, Mann DM, Owen F, Ironside JW, de Silva R (1995)
Allelic variations in apolipoprotein E and prion protein genotype related to
plaque formation and age of onset in sporadic Creutzfeldt-Jakob disease.
Neurosci Lett 187(2): 127–129.
31. Gambetti P, Kong Q, Zou W, Parchi P, Chen SG (2003) Sporadic and familial
CJD: classification and characterisation. Br Med Bull 66: 213–239.
32. Hill AF, Joiner S, Wadsworth JD, Sidle KC, Bell JE, et al. (2003) Molecular
classification of sporadic Creutzfeldt-Jakob disease. Brain 126(Pt 6): 1333–1346.
APOE-PRNP Interaction in AD and CJD
PLoS ONE | www.plosone.org 8 July 2011 | Volume 6 | Issue 7 | e2209033. Berr C, Richard F, Dufouil C, Amant C, Alperovitch A, et al. (1998)
Polymorphism of the prion protein is associated with cognitive impairment in the
elderly: the EVA study. Neurology 51(3): 734–737.
34. Giannattasio C, Poleggi A, Puopolo M, Pocchiari M, Antuono P, et al. (2008)
Survival in Alzheimer’s disease is shorter in women carrying heterozygosity at
codon 129 of the PRNP gene and no APOE epsilon 4 allele. Dement Geriatr
Cogn Disord 25(4): 354–358.
35. Parkin ET, Watt NT, Hussain I, Eckman EA, Eckman CB (2007) Cellular prion
protein regulates beta-secretase cleavage of the Alzheimer’s amyloid precursor
protein. Proc Natl Acad Sci U S A 104(26): 11062–11067.
36. Kellett KA, Hooper NM (2009) Prion protein and Alzheimer disease. Prion 3(4):
190–194.
37. Nygaard HB, Strittmatter SM (2009) Cellular prion protein mediates the toxicity
of beta-amyloid oligomers: implications for Alzheimer disease. Arch Neurol
66(11): 1325–1328.
38. Laure ´n J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM (2009) Cellular
prion protein mediates impairment of synaptic plasticity by amyloid-beta
oligomers. Nature 457(7233): 1128–1132.
39. Gunther EC, Strittmatter SM (2010) Beta-amyloid oligomers and cellular prion
protein in Alzheimer’s disease. J Mol Med 88(4): 331–338.
40. Chung E, Ji Y, Sun Y, Kascsak RJ, Kascsak RB, et al. (2010) Anti-PrPC
monoclonal antibody infusion as a novel treatment for cognitive deficits in an
Alzheimer’s disease model mouse. BMC Neurosci 11: 130.
41. Gimbel DA, Nygaard HB, Coffey EE, Gunther EC, Laure ´n J, et al. (2010)
Memory impairment in transgenic Alzheimer mice requires cellular prion
protein. J Neurosci 5;30(18): 6367–6374.
42. Price DL, Borchelt DR, Sisodia SS (1993) Alzheimer disease and the prion
disorders amyloid beta-protein and prion protein amyloidoses. Proc Natl Acad
Sci U S A 90(14): 6381–6384.
43. de Pedro-Cuesta J, Mahillo-Fernandez I, Rabano A, Calero M, Cruz M, et al.
(2011) Nosocomial transmission of sporadic Creutzfeldt-Jakob disease: results
from a risk-based assessment of surgical interventions. J Neurol Neurosurg
Psychiatry 82(2): 204–212.
44. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE (2007) Systematic
meta-analyses of Alzheimer disease genetic association studies: the AlzGene
database. Nat Genet 39(1): 17–23.
45. Combarros O, Cortina-Borja M, Smith AD, Lehmann DJ (2009) Epistasis in
sporadic Alzheimer’s disease. Neurobiol Aging 30(9): 1333–1349.
46. Schmidt C, Redyk K, Meissner B, Krack L, von Ahsen N, et al. (2010) Clinical
features of rapidly progressive Alzheimer’s disease. Dement Geriatr Cogn Disord
29(4): 371–378.
47. Debatin L, Streffer J, Geissen M, Matschke J, Aguzzi A, et al. (2008) Association
between deposition of beta-amyloid and pathological prion protein in sporadic
Creutzfeldt-Jakob disease. Neurodegener Dis 5(6): 347–354.
48. Hainfellner JA, Wanschitz J, Jellinger K, Liberski PP, Gullotta F, et al. (1998)
Coexistence of Alzheimer-type neuropathology in Creutzfeldt-Jakob disease.
Acta Neuropathol 96(2): 116–122.
49. Ferrer I, Blanco R, Carmona M, Puig B, Ribera R, et al. (2001) Prion protein
expression in senile plaques in Alzheimer’s disease. Acta Neuropathol 101(1):
49–56.
50. Voigtla ¨nder T, Klo ¨ppel S, Birner P, Jarius C, Flicker H, et al. (2001) Marked
increase of neuronal prion protein immunoreactivity in Alzheimer’s disease and
human prion diseases. Acta Neuropathol 101(5): 417–423.
51. Kovacs GG, Zerbi P, Voigtla ¨nder T, Strohschneider M, Trabattoni G, et al.
(2002) The prion protein in human neurodegenerative disorders. Neurosci Lett
329(3): 269–272.
52. Takahashi RH, Tobiume M, Sato Y, Sata T, Gouras GK, et al. (2010)
Accumulation of cellular prion protein within dystrophic neurites of amyloid
plaques in the Alzheimer’s disease brain. Neuropathology 2010 Nov 9: [Epub
ahead of print].
53. Morales R, Estrada LD, Diaz-Espinoza R, Morales-Scheihing D, Jara MC, et al.
(2010) Molecular cross talk between misfolded proteins in animal models of
Alzheimer’s and prion diseases. J Neurosci 30(13): 4528–4535.
54. Rushworth JV, Hooper NM (2010) Lipid Rafts: Linking Alzheimer’s Amyloid-b
Production, Aggregation, and Toxicity at Neuronal Membranes. Int J Alzheimers
Dis 2010 Dec 27.
55. Cerf E, Gustot A, Goormaghtigh E, Ruysschaert J.-M, Raussens V (2011) High
ability of apolipoprotein E4 to stabilize amyloid-b peptide oligomers, the
pathological entities responsible for Alzheimer’s disease. FASEB J, 2011 Jan 25.
[Epub ahead of print].
56. Kim J, Basak JM, Holtzman DM (2009) The role of apolipoprotein E in
Alzheimer’s disease. Neuron 63(3): 287–303.
57. Bu G (2009) Apolipoprotein E and its receptors in Alzheimer’s disease:
pathways, pathogenesis and therapy. Nat Rev Neurosci 10(5): 333–44.
58. Sharman MJ, Morici M, Hone E, Berger T, Taddei K, et al. (2010) APOE
genotype results in differential effects on the peripheral clearance of amyloid-
beta42 in APOE knock-in and knock-out mice. J Alzheimers Dis 21(2): 403–409.
59. Petrlova J, Hong HS, Bricarello DA, Harishchandra G, Lorigan GA, et al.
(2011) A differential association of Apolipoprotein E isoforms with the amyloid-b
oligomer in solution. Proteins 79(2): 402–416.
60. Hoe HS, Harris DC, Rebeck GW (2005) Multiple pathways of apolipoprotein E
signaling in primary neurons. J Neurochem 93(1): 145–55.
61. Kim D, Tsai LH (2009) Bridging physiology and pathology in AD. Cell 137(6):
997–1000.
62. Palmer MS, Dryden AJ, Hughes JT, Collinge J (1991) Homozygous prion
protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature
352(6333): 340–342.
63. Chiesa R, Piccardo P, Biasini E, Ghetti B, Harris DA (2008) Aggregated, wild-
type prion protein causes neurological dysfunction and synaptic abnormalities.
J Neurosci 28(49): 13258–13267.
64. Minaki H, Sasaki K, Honda H, Iwaki T (2009) Prion protein oligomers in
Creutzfeldt-Jakob disease detected by gel-filtration centrifuge columns. Neuro-
pathology 29(5): 536–542.
65. Gavı ´n R, Uren ˜a J, Rangel A, Pastrana MA, Requena JR, et al. (2008) Fibrillar
prion peptide PrP(106–126) treatment induces Dab1 phosphorylation and
impairs APP processing and Abeta production in cortical neurons. Neurobiol
Dis 30(2): 243–254.
66. Gavı ´n R, Ferrer I, del Rı ´o JA (2010) Involvement of Dab1 in APP processing
and beta-amyloid deposition in sporadic Creutzfeldt-Jakob patients. Neurobiol
Dis 37(2): 324–329.
67. Kesa ¨niemi YA, Ehnholm C, Miettinen TA (1987) Intestinal cholesterol
absorption efficiency in man is related to apoprotein E phenotype. J Clin Invest
80(2): 578–581.
68. Mahley RW, Huang Y (1999) Apolipoprotein E: from atherosclerosis to
Alzheimer’s disease and beyond. Curr Opin Lipidol 10(3): 207–217.
69. Gilch S, Kehler C, Scha ¨tzl HM (2006) The prion protein requires cholesterol for
cell surface localization. Mol Cell Neurosci 31(2): 346–353.
70. Huang Y (2010) Abeta-independent roles of apolipoprotein E4 in the
pathogenesis of Alzheimer’s disease. Trends Mol Med 16(6): 287–294.
71. Mead S, Stumpf MP, Whitfield J, Beck JA, Poulter M, et al. (2003) Balancing
selection at the prion protein gene consistent with prehistoric kurulike epidemics.
Science 300(5619): 640–643.
72. Eisenberg DT, Kuzawa CW, Hayes MG (2010) Worldwide allele frequencies of
the human apolipoprotein E gene: climate, local adaptations, and evolutionary
history. Am J Phys Anthropol 143(1): 100–111.
73. Soldevila M, Andre ´s AM, Ramı ´rez-Soriano A, Marque `s-Bonet T, Calafell F,
et al. (2006) The prion protein gene in humans revisited: lessons from a
worldwide resequencing study. Genome Res 16(2): 231–239.
74. Wade MJ (2001) Epistasis, complex traits, and mapping genes. Genetica 112–
113: 59–69.
75. Moore JH, Williams SM (2005) Traversing the conceptual divide between
biological and statistical epistasis: systems biology and a more modern synthesis.
Bioessays 27(6): 637–646.
76. Golanska E, Hulas-Bigoszewska K, Sieruta M, Zawlik I, Witusik M, et al. (2009)
Earlier onset of Alzheimer’s disease: risk polymorphisms within PRNP, PRND,
CYP46, and APOE genes. J Alzheimers Dis 17(2): 359–368.
77. McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. (1984)
Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work
Group under the auspices of Department of Health and Human Services Task
Force on Alzheimer’s Disease. Neurology 34(7): 939–944.
78. Calero O, Hortigu ¨ela R, Bullido MJ, Calero M (2009) Apolipoprotein E
genotyping method by real time PCR, a fast and cost-effective alternative to the
TaqMan and FRET assays. J Neurosci Methods 183(2): 238–240.
79. Martı ´nez-Garcı ´a A, Sastre I, Tenorio R, Bullido MJ (2004) SNP genotyping with
FRET probes. Optimizing the resolution of heterozygotes. Mol Cell Probes 18:
211–214.
80. Calero O, Hortigu ¨ela R, Albo C, de Pedro-Cuesta J, Calero M (2009) Allelic
discrimination of genetic human prion diseases by real-time PCR genotyping.
Prion 3(3): 146–150.
81. Cortina-Borja M, Smith AD, Combarros O, Lehmann DJ (2009) The synergy
factor: a statistic to measure interactions in complex diseases. BMC Res Notes 2:
105.
APOE-PRNP Interaction in AD and CJD
PLoS ONE | www.plosone.org 9 July 2011 | Volume 6 | Issue 7 | e22090